Sepsis Endotypes Defined by Lymphocyte Thresholds and Inflammation Inform Precision Immunomodulation

Abstract

Immunomodulatory therapies demonstrate variable efficacy in sepsis, suggesting biological heterogeneity inadequately captured by current stratification approaches. Although lymphopenia predicts mortality, functional thresholds and their interaction with inflammation remain poorly characterized. We investigated whether integrating lymphocyte status with systemic inflammation defines sepsis endotypes with differential treatment responsiveness. We retrospectively profiled 714 patients within 24 h using lymphocyte subsets and inflammatory biomarkers. Restricted cubic spline analysis revealed nonlinear associations between lymphocyte counts and mortality (p < 0.01), with steep risk increases at lower counts. Risk optimization identified critical thresholds at 374 cells/µL (total T cells), 340 cells/µL (CD4⁺), and 157 cells/µL (CD8⁺). Principal component analysis of inflammatory markers combined with lymphocyte stratification classified patients into four discrete endotypes with markedly divergent 28-day survival (55%–58% vs. 82–87%, p < 0.001). Patients with immunosuppressed/hypo-inflammatory endotype had higher survival among those who received corticosteroids (CD4⁺-depleted: 84.4% vs. 75.6%, p < 0.001; T-cell-depleted: 78.7% vs. 72.3%, p = 0.006), whereas hyperinflammatory endotypes showed no such association. Integration of publicly available single-cell (GSE167363) and bulk transcriptomics (GSE65682) datasets yielded a 15-gene T-cell dysfunction signature with external validation (CNP0004962, area under the curve [AUC] 0.76–0.85). These observational findings suggest that immune-inflammatory co-profiling identifies biologically distinct sepsis subgroups with differential treatment associations, generating testable hypotheses for prospective validation through endotype-guided trials.

Keywords

biomarker-guided therapy / corticosteroids / immunomodulation / lymphocyte dysfunction / sepsis endotypes

References

[1] K. E. Rudd, S. C. Johnson, K. M. Agesa, et al., “Global, Regional, and National Sepsis Incidence and Mortality, 1990–2017: Analysis for the Global Burden of Disease Study,” Lancet 395, no. 10219 (2020): 200–211.

[2] H. C. Prescott and D. C. Angus, “Enhancing Recovery From Sepsis: A Review,” JAMA 319, no. 1 (2018): 62–75.

[3] M. Cecconi, L. Evans, M. Levy, and A. Rhodes, “Sepsis and Septic Shock,” Lancet 392, no. 10141 (2018): 75–87.

[4] T. van der Poll, F. L. van de Veerdonk, B. P. Scicluna, and M. G. Netea, “The Immunopathology of Sepsis and Potential Therapeutic Targets,” Nature Reviews Immunology 17, no. 7 (2017): 407–420.

[5] F. Venet and G. Monneret, “Advances in the Understanding and Treatment of Sepsis-Induced Immunosuppression,” Nature Reviews Nephrology 14, no. 2 (2018): 121–137.

[6] J. S. Boomer, K. To, K. C. Chang, et al., “Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure,” JAMA 306, no. 23 (2011): 2594–2605.

[7] R. S. Hotchkiss, G. Monneret, and D. Payen, “Sepsis-Induced Immunosuppression: From Cellular Dysfunctions to Immunotherapy,” Nature Reviews Immunology 13, no. 12 (2013): 862–874.

[8] D. Annane, S. M. Pastores, B. Rochwerg, et al., “Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017,” Intensive Care Medicine 43, no. 12 (2017): 1751–1763.

[9] N. K. Patil, J. K. Bohannon, and E. R. Sherwood, “Immunotherapy: A Promising Approach to Reverse Sepsis-Induced Immunosuppression,” Pharmacological Research 111 (2016): 688–702.

[10] C. W. Seymour, J. N. Kennedy, S. Wang, et al., “Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis,” JAMA 321, no. 20 (2019): 2003–2017.

[11] T. E. Sweeney, T. D. Azad, M. Donato, et al., “Unsupervised Analysis of Transcriptomics in Bacterial Sepsis Across Multiple Datasets Reveals Three Robust Clusters,” Critical Care Medicine 46, no. 6 (2018): 915–925.

[12] E. E. Davenport, K. L. Burnham, J. Radhakrishnan, et al., “Genomic Landscape of the Individual Host Response and Outcomes in Sepsis: A Prospective Cohort Study,” Lancet Respiratory Medicine 4, no. 4 (2016): 259–271.

[13] B. Venkatesh, S. Finfer, J. Cohen, et al., “Adjunctive Glucocorticoid Therapy in Patients With Septic Shock,” New England Journal of Medicine 378, no. 9 (2018): 797–808.

[14] D. Annane, A. Renault, C. Brun-Buisson, et al., “Hydrocortisone Plus Fludrocortisone for Adults With Septic Shock,” New England Journal of Medicine 378, no. 9 (2018): 809–818.

[15] A. C. Gordon, A. J. Mason, N. Thirunavukkarasu, et al., “Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial,” JAMA 316, no. 5 (2016): 509–518.

[16] B. Francois, R. Jeannet, T. Daix, et al., “Interleukin-7 Restores Lymphocytes in Septic Shock: The IRIS-7 Randomized Clinical Trial,” JCI Insight 3, no. 5 (2018): e98960.

[17] H. C. Prescott, C. S. Calfee, B. T. Thompson, D. C. Angus, and V. X. Liu, “Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design,” American Journal of Respiratory and Critical Care Medicine 194, no. 2 (2016): 147–155.

[18] D. C. Angus and T. van der Poll, “Severe Sepsis and Septic Shock,” New England Journal of Medicine 369, no. 9 (2013): 840–851.

[19] A. M. Drewry, N. Samra, L. P. Skrupky, B. M. Fuller, S. M. Compton, and R. S. Hotchkiss, “Persistent Lymphopenia After Diagnosis of Sepsis Predicts Mortality,” Shock 42, no. 5 (2014): 383–391.

[20] D. Andaluz-Ojeda, V. Iglesias, F. Bobillo, et al., “Early Natural Killer Cell Counts in Blood Predict Mortality in Severe Sepsis,” Critical Care 15, no. 5 (2011): R243.

[21] R. S. Hotchkiss, K. W. Tinsley, P. E. Swanson, et al., “Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans,” Journal of Immunology 166, no. 11 (2001): 6952–6963.

[22] I. J. Jensen, F. V. Sjaastad, T. S. Griffith, and V. P. Badovinac, “Sepsis-Induced T Cell Immunoparalysis: The Ins and Outs of Impaired T Cell Immunity,” Journal of Immunology 200, no. 5 (2018): 1543–1553.

[23] S. Inoue, K. Suzuki, Y. Komori, et al., “Persistent Inflammation and T Cell Exhaustion in Severe Sepsis in the Elderly,” Critical Care 18, no. 3 (2014): R130.

[24] L. F. Gentile, A. G. Cuenca, P. A. Efron, et al., “Persistent Inflammation and Immunosuppression: A Common Syndrome and New Horizon for Surgical Intensive Care,” Journal of Trauma and Acute Care Surgery 72, no. 6 (2012): 1491–1501.

[25] M. J. Delano and P. A. Ward, “The Immune System's Role in Sepsis Progression, Resolution, and Long-Term Outcome,” Immunological Reviews 274, no. 1 (2016): 330–353.

[26] D. Grimaldi, S. Louis, F. Pène, et al., “Profound and Persistent Decrease of Circulating Dendritic Cells Is Associated With ICU-Acquired Infection in Patients With Septic Shock,” Intensive Care Medicine 37, no. 9 (2011): 1438–1446.

[27] A. Spec, Y. Shindo, C. A. Burnham, et al., “T Cells From Patients With Candida Sepsis Display a Suppressive Immunophenotype,” Critical Care 20 (2016): 15.

[28] M. Reyes, M. R. Filbin, R. P. Bhattacharyya, et al., “An Immune-Cell Signature of Bacterial Sepsis,” Nature Medicine 26, no. 3 (2020): 333–340.

[29] S. C. Cheng, B. P. Scicluna, R. J. Arts, et al., “Broad Defects in the Energy Metabolism of Leukocytes Underlie Immunoparalysis in Sepsis,” Nature Immunology 17, no. 4 (2016): 406–413.

[30] B. P. Scicluna, L. A. van Vught, A. H. Zwinderman, et al., “Classification of Patients With Sepsis According to Blood Genomic Endotype: A Prospective Cohort Study,” Lancet Respiratory Medicine 5, no. 10 (2017): 816–826.

[31] T. E. Sweeney, A. Shidham, H. R. Wong, and P. Khatri, “A Comprehensive Time-Course-Based Multicohort Analysis of Sepsis and Sterile Inflammation Reveals a Robust Diagnostic Gene Set,” Science Translational Medicine 7, no. 287 (2015): 287ra71.

[32] X. Qiu, J. Li, J. Bonenfant, et al., “Dynamic Changes in Human Single-Cell Transcriptional Signatures During Fatal Sepsis,” Journal of Leukocyte Biology 110, no. 6 (2021): 1253–1268.

[33] B. P. Scicluna, P. M. Klein Klouwenberg, and L. A. van Vught, “A Molecular Biomarker to Diagnose Community-Acquired Pneumonia on Intensive Care Unit Admission,” American Journal of Respiratory and Critical Care Medicine 192, no. 7 (2015): 826–835.

[34] W. Wang, C. Tan, L. Li, et al., “The China National GeneBank Sequence Archive (CNSA) 2024 Update,” Horticulture Research 12, no. 5 (2025): uhaf036.

[35] Z. Feng, L. Wang, J. Yang, et al., “Sepsis: The Evolution of Molecular Pathogenesis Concepts and Clinical Management,” MedComm 6, no. 3 (2025): e70109.

[36] R. S. Hotchkiss, G. Monneret, and D. Payen, “Immunosuppression in Sepsis: A Novel Understanding of the Disorder and a New Therapeutic Approach,” Lancet Infectious Diseases 13, no. 3 (2013): 260–268.

[37] J. S. Boomer, J. M. Green, and R. S. Hotchkiss, “The Changing Immune System in Sepsis: Is Individualized Immuno-Modulatory Therapy the Answer?,” Virulence 5, no. 1 (2014): 45–56.

[38] M. Singer, “The Role of Mitochondrial Dysfunction in Sepsis-Induced Multi-Organ Failure,” Virulence 5, no. 1 (2014): 66–72.

[39] L. K. Mackay and A. Kallies, “Transcriptional Regulation of Tissue-Resident Lymphocytes,” Trends in Immunology 38, no. 2 (2017): 94–103.

[40] Y. H. Huang, D. Li, A. Winoto, and E. A. Robey, “Distinct Transcriptional Programs in Thymocytes Responding to T Cell Receptor, Notch, and Positive Selection Signals,” PNAS 101, no. 14 (2004): 4936–4941.

[41] M. Singer, C. S. Deutschman, C. W. Seymour, et al., “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3),” JAMA 315, no. 8 (2016): 801–810.

[42] D. B. Rubin and N. Schenker, “Multiple Imputation in Health-Care Databases: An Overview and Some Applications,” Statistics in Medicine 10, no. 4 (1991): 585–598.

[43] F. E. Harrell,, K. L. Lee, and D. B. Mark, “Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors,” Statistics in Medicine 15, no. 4 (1996): 361–387.

[44] T. Stuart, A. Butler, P. Hoffman, et al., “Comprehensive Integration of Single-Cell Data,” Cell 177, no. 7 (2019): 1888–1902.e21.

[45] A. Daneshvar and G. Mousa, “Regression Shrinkage and Selection via Least Quantile Shrinkage and Selection Operator,” PLoS ONE 18, no. 2 (2023): e0266267.

[46] E. W. Steyerberg, A. J. Vickers, N. R. Cook, et al., “Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures,” Epidemiology 21, no. 1 (2010): 128–138.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.